Being ‘skinny fat’ raises the risk of Alzheimer’s even MORE than typical obesity, small study suggests

  • Visceral fat, which is found around organs deep in the body, has been linked to the disease
  • The hidden fat causes inflammation, which leads to inflammation in the brain
  • READ MORE: Multiple sclerosis drugs may treat Alzheimer’s disease

Being ‘skinny fat’ increases the risk of Alzheimer’s disease – perhaps even more than apparently obese people, research suggests.

A small study of 56 middle-aged people found that people with higher levels of visceral fat – the type that wraps around abdominal organs deep within the body – had more danger proteins in their brains linked to dementia than their counterparts who had more had weak fat, the so-called subcutaneous fat.

Visceral fat is known as ‘skinny fat’ because it is not visible from the outside, meaning that even people with a healthy BMI can have a significant amount of visceral fat.

But it can release chemicals and hormones into the blood that cause inflammation, which in turn causes inflammation in the brain, which is one of the main causes of Alzheimer’s disease.

Visceral fat wraps around abdominal organs deep within the body, while subcutaneous fat is located under the skin. Even people with a healthy BMI can have a significant amount of visceral fat

Study author Dr. Mahsa Dolatshahi, a postdoctoral researcher at Washington University in St. Louis, said: ‘Although there have been other studies linking BMI to brain atrophy or even a higher risk of dementia, no previous study has identified a specific type of dementia in associated. fat to the actual protein of Alzheimer’s disease in cognitively normal people.’

Researchers looked at data from 54 cognitively healthy participants aged 40-60 with an average BMI of 32.

A BMI over 30 is categorized as obese, according to the Centers for Disease Control and Prevention.

The volume of subcutaneous fat and visceral fat was measured once using an MRI.

Subcutaneous fat is the wobbly type of fat that lies just under the skin and causes cellulite to develop.

This type of fat is actually the least harmful and tends to accumulate around the thighs and buttocks rather than around the intestines, creating a pear-shaped body.

Unlike visceral fat, subcutaneous fat does not release chemicals and forms the layer between the skin and the muscles.

An MRI of the participants’ brains also measured the thickness of the cortex, the layer of the brain responsible for speech, long-term memory, perception and judgment. As Alzheimer’s disease worsens, this layer becomes thinner.

At the same time, PET scans were also used in a subset of participants to see if amyloid and tau proteins were at higher levels.

A positron emission tomography (PET) scan is used to check for signs of brain disease, as well as heart disease and cancer.

Amyloid and tau are proteins that are thought to disrupt communication between brain cells and are important markers of Alzheimer’s disease.

The researchers compared the fat measurements and the brain scans and found that participants with more visceral fat had more amyloid in their brains, indicating they may be at higher risk for Alzheimer’s disease. The relationship was worse among men than among women.

Researchers found that this fat is linked to changes in participants’ brains as early as age 50 – up to 15 years before the first symptoms of Alzheimer’s memory loss.

The researchers plan to follow the study participants to monitor the long-term effects of visceral fat, as the earliest development of Alzheimer’s disease in the brain can occur up to 20 years before the first symptoms.

Senior study author Dr. Cyrus Raji, associate professor of radiology and neurology, said the findings could help earlier diagnosis of Alzheimer’s disease and possible treatments.

He said: ‘It shows that on average, such brain changes occur as early as the age of 50 – up to 15 years before the first symptoms of Alzheimer’s memory loss appear.’

The study was presented at the annual meeting of the Radiology Society of North America.

According to the Alzheimer’s Association, more than six million Americans suffer from Alzheimer’s disease, which is expected to rise to 13 million by 2050.

What is Alzheimer’s disease and how is it treated?

Alzheimer’s disease is a progressive, degenerative disease of the brain in which the buildup of abnormal proteins causes nerve cells to die.

This disrupts the transmitters that transmit messages and causes the brain to shrink.

More than 6 million people suffer from the disease in the US, where it is the sixth leading cause of death, and more than 1 million Britons have the disease.

WHAT IS HAPPENING?

As brain cells die, the functions they provide are lost.

That includes memory, orientation and the ability to think and reason.

The progression of the disease is slow and gradual.

On average, patients live five to seven years after diagnosis, but some can live another ten to fifteen years.

EARLY SYMPTOMS:

  • Loss of short-term memory
  • Disorientation
  • Behavioral changes
  • Mood swings
  • Problems handling money or making a phone call

LATER SYMPTOMS:

  • Severe memory loss, forgetting close relatives, familiar objects or places
  • Becoming anxious and frustrated about the inability to understand the world, leading to aggressive behavior
  • Eventually you lose the ability to walk
  • May have problems eating
  • The majority will eventually need 24-hour care

HOW IT IS TREATED?

There is no known cure for Alzheimer’s disease.

However, there are some treatments available that help relieve some of the symptoms.

One of these is acetylcholinesterase inhibitors, which help brain cells communicate with each other.

Another example is menantine, which works by blocking a chemical called glutamate, which can build up in the brains of people with Alzheimer’s disease and inhibit mental function.

As the disease progresses, Alzheimer’s patients may exhibit aggressive behavior and/or suffer from depression. Medications may be provided to help relieve these symptoms.

Other non-pharmaceutical treatments, such as mental training to improve memory and combat one aspect of Alzheimer’s disease, are also recommended.

Source: Alzheimer’s Association and the NHS

Related Post